Precancerous cells in the uterus are most often treated with progestin hormone therapy, a hormonal IUD, or hysterectomy, depending on the severity of the changes and whether you want to preserve fertility. The good news is that most cases respond well to treatment, especially when caught early. The specific approach depends on whether the abnormal cells show “atypia,” a feature that significantly raises the risk of progression to cancer.
Two Types, Two Levels of Risk
When a biopsy reveals precancerous changes in the uterine lining, the diagnosis falls into one of two main categories. The first is hyperplasia without atypia, where the lining has thickened abnormally but the cells themselves still look relatively normal. This carries a low risk of becoming cancer: about 1.6% progression risk, with a cumulative 20-year risk under 5%.
The second and more serious category is atypical hyperplasia, also called endometrial intraepithelial neoplasia (EIN). Here, the cells have started to look abnormal under a microscope, with crowded glandular architecture and visibly altered cells. This is a direct precursor to uterine cancer. Without effective treatment, 20 to 50% of women with atypical hyperplasia will develop endometrial cancer, with one large study placing the progression risk at about 23%.
Hormonal Treatment With Progestin
Progestin, a form of the hormone progesterone, is the cornerstone of non-surgical treatment. It works by thinning the uterine lining and counteracting the excess estrogen that drove the abnormal growth in the first place. Progestin can be delivered in two main ways: as an oral medication or through a hormonal IUD that releases the hormone directly into the uterus.
The hormonal IUD (levonorgestrel-releasing IUD) is widely considered the most effective option because it delivers a continuous, concentrated dose of progestin right where it’s needed. Research on the Mirena IUD showed that 54% of women with EIN had regression by 3 months, rising to 73% by 9 months and 88% by 12 months of continuous use. Another levonorgestrel IUD (Liletta) showed even higher regression rates in a comparative study: 80% at 3 months and 100% at 9 months, though the sample sizes were small. The IUD also has fewer systemic side effects than oral progestin, since most of the hormone stays local.
Oral progestin is an alternative, particularly for women who can’t use an IUD. It’s taken daily or in a cyclical pattern. Side effects can include bloating, mood changes, and irregular bleeding, which are more noticeable with oral forms than with the IUD.
When Hysterectomy Is Recommended
For atypical hyperplasia or EIN, hysterectomy (surgical removal of the uterus) is the most definitive treatment because it eliminates both the precancerous cells and any risk of them progressing. It’s generally recommended as the primary option for women who have completed childbearing, especially given that up to 40 to 50% of untreated atypical hyperplasia cases can advance to cancer.
Hysterectomy is also recommended when hormonal treatment hasn’t worked. Current guidelines suggest that if there’s no response to progestin therapy after 9 to 12 months, it’s time to discuss surgical options. The procedure is typically done minimally invasively (laparoscopic or robotic), which means a shorter recovery of about 2 to 4 weeks for most women compared to open surgery.
For hyperplasia without atypia, hysterectomy is rarely the first step. Hormonal treatment is usually tried first, and surgery is reserved for cases that don’t respond or keep recurring.
Preserving Fertility During Treatment
If you want to have children in the future, hormonal therapy with close monitoring is the standard fertility-sparing approach. This typically means a progestin-releasing IUD or oral progestin, paired with regular biopsies to confirm the precancerous cells are responding. The goal is to achieve regression (normal biopsy results) and then pursue pregnancy relatively soon, since the condition can recur.
This path requires a serious commitment to follow-up. You’ll need endometrial biopsies every 3 to 6 months, and the monitoring continues for up to 2 years even after the cells return to normal. Once you’ve completed your family, hysterectomy is typically discussed to eliminate the ongoing risk of recurrence.
How Weight Loss and Metformin Help
Excess body fat produces estrogen, which fuels the overgrowth of the uterine lining. Losing weight directly addresses this root cause. A study found that women who lost more than 3% of their body weight while on progestin therapy had a 91.2% disease reversal rate, compared to lower rates in those who didn’t lose weight. That’s a meaningful boost from a relatively modest amount of weight loss.
Metformin, a medication commonly used for blood sugar management, also showed a striking benefit. Women using metformin alongside progestin had a 93.2% reversal rate, compared to just 52.4% in the group not taking it. Both weight loss and metformin were independently associated with better outcomes, meaning each one helps on its own, and combining progestin with both appears more effective than progestin alone.
What Monitoring Looks Like
Treatment for precancerous uterine cells isn’t a one-and-done situation. Regular biopsies are essential to confirm the cells are responding and to catch any recurrence early. The monitoring schedule depends on your diagnosis.
For hyperplasia without atypia, guidelines recommend a biopsy about 3 months into treatment, then follow-up biopsies until you have at least two consecutive normal results at 6-month intervals. If you’re at higher risk for recurrence (due to obesity or other factors), annual follow-up may continue long term.
For atypical hyperplasia or EIN, monitoring is more intensive. You can expect endometrial biopsies every 3 to 6 months for up to 2 years. If the abnormal cells haven’t cleared after 9 to 12 months of treatment, your doctor will likely discuss switching strategies or proceeding with hysterectomy. For women who keep their uterus after successful treatment, some guidelines recommend ongoing biopsies every 6 to 12 months indefinitely, given the risk of recurrence.
The biopsies themselves are office procedures that take a few minutes. They can cause cramping similar to a bad period cramp, and most women manage them with over-the-counter pain relief beforehand. While the monitoring schedule sounds intensive, it’s what makes conservative treatment safe, ensuring that any changes are caught well before they could progress to cancer.